about
Hospital cluster of HBV infection: molecular evidence of patient-to-patient transmission through lancing device.Gastrointestinal emergencies in patients with acute intestinal graft-versus-host disease.HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature.Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysisUnrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis.Homecare-based Motor Rehabilitation in Musculoskeletal Chronic Graft Versus Host Disease.Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO eraAlgorithm for donor selection in 2011.Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation.The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network.The surgical choice in neutropenic patients with hematological disorders and acute abdominal complications.A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.Stem cell transplantation for chronic myeloid leukemia in children.Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders.Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia.Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.Bowel ultrasonography as an aid for diagnosis of intestinal acute graft-versus-host-disease after allogeneic haematopoietic stem cell transplantation.Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.3-Tesla MR spectroscopy in patients subjected to bone marrow transplantation: clinical correlations.A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient.Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.Quality assessment of cord blood units selected for unrelated transplantation: a transplant center perspective.Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up.N-acetylcysteine in the treatment of steroid-resistant acute graft-versus-host-disease: preliminary results. Gruppo Italiano Trapianto di Midollo Osseo (GITMO).Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European surveyCytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemiaComparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemiaTransplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute LeukemiaImpact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission
P50
Q31050747-1874C3CF-70E9-4CDA-9470-A77D23574898Q33502865-904196D4-368F-4970-972B-B50449333197Q34572795-D2CDF1FF-D4A9-4E08-AE1F-69DF3B47BBF1Q35084714-ED2D8990-19C8-4744-9334-5A8F24CDE48DQ35185685-5E4ED1E7-A51B-4A40-B9DA-B6CAE3EED848Q35200293-E83A9FAA-DC5D-4F9D-AEC3-FAFBA655762EQ35245087-E174A2B8-F84D-4BF4-A835-CE622CF2D029Q36166896-748A6A43-F6C8-4BAF-902A-D60E3241457EQ36366631-DA683DB4-DC46-454A-A879-31A803AC03DAQ37938486-CF3F9E1C-4E2F-4741-8ECE-E5134CC1B034Q37950999-E0CFF9EC-9A0C-4E3B-87C1-6AE56553EA21Q42974996-1DEFB991-BFB0-4556-8E80-96AF26674C5AQ43018612-E3E215F0-05BD-4441-8F98-D34AFA71EC62Q43049406-8F77EF45-E4EF-4585-8699-6FD1B4E43E89Q43445569-3F2DB689-3B65-4A17-A927-A52BD299BD7DQ43857878-4A9CCEE3-A350-4D37-9496-87268E63B82AQ44103814-D0FBE9FD-413C-4962-A78F-D9B4673690CEQ44417169-19D70248-2E23-439A-80DD-CD072BB644ECQ44638272-E5759BA2-B6BA-41D4-84A4-911E72891D0AQ45145867-ED400BFA-5701-4C45-9293-5C9E922359FAQ45147355-210C5A00-7C93-4BB6-ADEB-5F6BE1200252Q45210269-65665F1A-1947-4D59-8E1F-001697056350Q45285591-B1C9B9FE-B99E-47F3-9F91-F282B9F87872Q45365219-52B7DADE-4FC2-442F-BB63-808F70BE8D4DQ45886829-D579A1B2-4A48-4258-A83A-72BC47C40CA8Q46016339-8DB36393-24EE-4531-A27D-7919732B196EQ46040482-18C178FF-6F61-48C9-8CBE-FAFD07D3D550Q46497211-6CF1A9A8-A761-42DE-9A0C-4C7F6F9E74B8Q46921558-57C79C25-578A-44C5-92A6-A606C06D6201Q47860858-9F9BECEC-8D1A-468C-A263-B53347EE3BF1Q50142348-8FD97A00-4ACE-4FB5-AF36-F7C29D481CFDQ50859540-99F941F2-DA71-42FA-93CC-2BF9B7CE97FBQ51764847-C6B80144-4B53-4EE6-B77A-A40C9CEA87C3Q53539694-91167132-74D6-463E-A66A-228508D308E5Q54071493-36AF7001-BD3A-4C73-9C87-F1B21113FE90Q56890433-1BEAF5B4-BEAB-4279-B9D6-0550FAFF5710Q58370816-017D8AA8-7FBD-45D4-9074-6BBE02EE4AB1Q58416305-30A997FE-DFA1-46C4-A35F-76AF128466F7Q58865943-49EA6AB3-9B6A-4ED4-BAAD-863D38CA51CDQ60211018-98624737-80AA-443F-9915-AC78F56B18B5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William Arcese
@ast
William Arcese
@en
William Arcese
@es
William Arcese
@nl
William Arcese
@sl
type
label
William Arcese
@ast
William Arcese
@en
William Arcese
@es
William Arcese
@nl
William Arcese
@sl
prefLabel
William Arcese
@ast
William Arcese
@en
William Arcese
@es
William Arcese
@nl
William Arcese
@sl
P106
P21
P31
P496
0000-0001-5697-366X